Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies

Targeted neurotrophic tropomyosin receptor kinase (TRK) inhibitors offer a highly specific therapeutic option for patients with infantile fibrosarcoma (IFS) carrying the NTRK gene translocation. International recommendations are needed to define the role of TRK inhibitors (TRKI) for infants with IFS. We analysed retrospective data for all published patients with IFS in the European Paediatric Soft tissue sarcoma Study Group and Cooperative Weichteilsarkomstudiengruppe (CWS) experience and developed a consensus strategy with the Children's Oncology Group.

Source: European Journal of Cancer - August 8, 2020 Category: Cancer & Oncology Authors: Daniel Orbach, Monika Sparber-Sauer, Theodore W. Laetsch, Veronique Minard-Colin, Stefan S. Bielack, Michela Casanova, Nadege Corradini, Ewa Koscielniak, Monika Scheer, Simone Hettmer, Gianni Bisogno, Douglas S. Hawkins, Andrea Ferrari Tags: Current Perspective Source Type: research